Genmab — Earnings Release 2010

Feb 3, 2011

News Details

Ad-hoc | 3 February 2011 13:04

Arzerra Fourth Quarter and Full Year 2010 Net Sales Figures

Genmab A/S

03.02.2011 13:04

Dissemination of a Adhoc News, transmitted by DGAP - a company of
EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---

-- Arzerra net sales in the fourth quarter of 2010 totaled GBP 9 million (DKK
77 million)
-- Full year 2010 Arzerra net sales were GBP 31 million (DKK 270 million)
-- Driving Genmab royalty income DKK 15.5 million for Q4 and DKK 54.1 million
for the full year

Copenhagen, Denmark; February 3, 2011 -Genmab A/S (OMX: GEN) announced today
that the net sales for Arzerra(r) (ofatumumab) during the fourth quarter of 2010
were GBP 9 million (approximately DKK 77 million). Arzerra fourth quarter net
sales in the U.S. and the rest of the world were GBP 7 million (approximately
DKK 60 million) and GBP 2 million (approximately DKK 17 million) respectively.
Under the terms of the collaboration with GlaxoSmithKline (GSK), Genmab expects
to receive a royalty payment of approximately DKK 15.5 million.

Full year 2010 net sales of Arzerra totaled GBP 31 million (approximately DKK
270 million) worldwide, resulting in total royalty income to Genmab of DKK 54.1
million for the year.

'We are pleased to announce the first full year of Arzerra sales figures and
expect to see an increase in sales in 2011 driven by the continued
commercialization and reimbursement within the EU and US,' said Jan van de
Winkel, Ph.D., Chief Executive Officer of Genmab.

Arzerra was granted accelerated approval by the FDA in October 2009, for the
treatment of patients in the U.S. with chronic lymphocytic leukemia (CLL) that
is refractory to fludarabine and alemtuzumab. Arzerra was launched by GSK in
mid-November 2009. In April 2010, a conditional marketing authorization for the
treatment of CLL in patients who are refractory to fludarabine and alemtuzumab
was granted by the EU Commission.

The conversion from GBP to DKK has been made using the Danish Central Bank
average rates for the respective quarters in 2010.

About Genmab A/S
Genmab is a leading international biotechnology company focused on developing
fully human antibody therapeutics for the potential treatment of cancer.
Genmab's world class discovery and development teams are using cutting-edge
technology to create and develop products to address unmet medical needs. Our
primary goal is to improve the lives of patients who are in urgent need of new
treatment options. For more information on Genmab's products and technology,
visit www.genmab.com.

Contact:
Helle Husted, Vice President, Investor Relations
T: +45 33 44 77 30; M: +45 25 27 47 13; E: h.husted@genmab.com

This Stock Exchange Release contains forward looking statements. The words
'believe', 'expect', 'anticipate', 'intend' and 'plan' and similar expressions
identify forward looking statements. Actual results or performance may differ
materially from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with
product discovery and development, uncertainties related to the outcome and
conduct of clinical trials including unforeseen safety issues, uncertainties
related to product manufacturing, the lack of market acceptance of our
products, our inability to manage growth, the competitive environment in
relation to our business area and markets, our inability to attract and retain
suitably qualified personnel, the unenforceability or lack of protection of our
patents and proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our products obsolete,
and other factors. For a further discussion of these risks, please refer to the
section 'Risk Management' in Genmab's Annual Report, which is available on
www.genmab.com. Genmab does not undertake any obligation to update or revise
forward looking statements in this Stock Exchange Release nor to confirm such
statements in relation to actual results, unless required by law.

Genmab(r); the Y-shaped Genmab logo(r); HuMax(r); HuMax-CD20(r);
HuMax-EGFr?;HuMax-IL8?;HuMax-TAC?; HuMax-CD38?; HuMax-TF?; HuMax-Her2?;
HuMax-Wnt?; HuMax-cMet?, DuoBody? and UniBody(r)are all trademarks of Genmab A/S.
Arzerra(r)is a trademark of GlaxoSmithKline.

Stock Exchange Release no. 02
CVR no. 2102 3884

Genmab A/S
Bredgade 34
1260 Copenhagen K
Denmark
News Source: NASDAQ OMX

03.02.2011 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: Genmab A/S

          Denmark

Phone:
Fax:
E-mail:
Internet:
ISIN: DK0010272202
WKN:

End of Announcement DGAP News-Service

---